JOURNAL ARTICLE
RESEARCH SUPPORT, NON-U.S. GOV'T
Add like
Add dislike
Add to saved papers

Neodymium-YAG laser iridotomy in the treatment and prevention of angle closure glaucoma. A review of 373 eyes.

The records of 271 consecutive patients (373 eyes) who underwent neodymium-YAG laser iridotomy at our institution over a period of 12 months were reviewed. The majority of eyes (60.5%) were treated for chronic primary angle closure glaucoma, 23.3% had prophylactic iridotomy for occludable angles, 7.8% were treated for acute angle closure glaucoma, 3.2% required iridotomy for the relief of iris bombé secondary to anterior uveitis, and the rest (5.2%) were treated for miscellaneous causes of secondary angle closure. Laser iridotomy, with or without medical treatment, obviated further surgical treatment in most categories of eyes. Visual acuity remained unchanged or improved in the great majority (92%) of cases over the period of follow-up (range, two to 12 months; median, four months). Visual deterioration in 8% of eyes was attributed to the usual causes, such as normal cataract progression, but none was believed to be related to the laser treatment. This article discusses the advantages of the neodymium-YAG laser (over argon) for performing iridotomies.

Full text links

We have located links that may give you full text access.
Can't access the paper?
Try logging in through your university/institutional subscription. For a smoother one-click institutional access experience, please use our mobile app.

For the best experience, use the Read mobile app

Mobile app image

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

By using this service, you agree to our terms of use and privacy policy.

Your Privacy Choices Toggle icon

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app